278 related articles for article (PubMed ID: 10346910)
1. The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter.
Romsicki Y; Sharom FJ
Biochemistry; 1999 May; 38(21):6887-96. PubMed ID: 10346910
[TBL] [Abstract][Full Text] [Related]
2. Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains.
Liu R; Sharom FJ
Biochemistry; 1996 Sep; 35(36):11865-73. PubMed ID: 8794769
[TBL] [Abstract][Full Text] [Related]
3. Fluorescence studies on the nucleotide binding domains of the P-glycoprotein multidrug transporter.
Liu R; Sharom FJ
Biochemistry; 1997 Mar; 36(10):2836-43. PubMed ID: 9062112
[TBL] [Abstract][Full Text] [Related]
4. Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport.
Eckford PD; Sharom FJ
Biochemistry; 2008 Dec; 47(51):13686-98. PubMed ID: 19049391
[TBL] [Abstract][Full Text] [Related]
5. Interaction of P-glycoprotein with defined phospholipid bilayers: a differential scanning calorimetric study.
Romsicki Y; Sharom FJ
Biochemistry; 1997 Aug; 36(32):9807-15. PubMed ID: 9245413
[TBL] [Abstract][Full Text] [Related]
6. Quantification and characterization of P-glycoprotein-substrate interactions.
Gatlik-Landwojtowicz E; Aänismaa P; Seelig A
Biochemistry; 2006 Mar; 45(9):3020-32. PubMed ID: 16503657
[TBL] [Abstract][Full Text] [Related]
7. Stoichiometry and affinity of nucleotide binding to P-glycoprotein during the catalytic cycle.
Qu Q; Russell PL; Sharom FJ
Biochemistry; 2003 Feb; 42(4):1170-7. PubMed ID: 12549939
[TBL] [Abstract][Full Text] [Related]
8. Proximity of the nucleotide binding domains of the P-glycoprotein multidrug transporter to the membrane surface: a resonance energy transfer study.
Liu R; Sharom FJ
Biochemistry; 1998 May; 37(18):6503-12. PubMed ID: 9572868
[TBL] [Abstract][Full Text] [Related]
9. The multi-drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P-glycoprotein by an allosteric interaction.
Martin C; Berridge G; Higgins CF; Callaghan R
Br J Pharmacol; 1997 Oct; 122(4):765-71. PubMed ID: 9375975
[TBL] [Abstract][Full Text] [Related]
10. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
Döppenschmitt S; Langguth P; Regårdh CG; Andersson TB; Hilgendorf C; Spahn-Langguth H
J Pharmacol Exp Ther; 1999 Jan; 288(1):348-57. PubMed ID: 9862789
[TBL] [Abstract][Full Text] [Related]
11. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells.
Gayet L; Dayan G; Barakat S; Labialle S; Michaud M; Cogne S; Mazane A; Coleman AW; Rigal D; Baggetto LG
Biochemistry; 2005 Mar; 44(11):4499-509. PubMed ID: 15766280
[TBL] [Abstract][Full Text] [Related]
12. A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein.
Garrigues A; Nugier J; Orlowski S; Ezan E
Anal Biochem; 2002 Jun; 305(1):106-14. PubMed ID: 12018951
[TBL] [Abstract][Full Text] [Related]
13. Localization of multidrug transporter substrates within model membranes.
Siarheyeva A; Lopez JJ; Glaubitz C
Biochemistry; 2006 May; 45(19):6203-11. PubMed ID: 16681393
[TBL] [Abstract][Full Text] [Related]
14. Drug binding and nucleotide hydrolyzability are essential requirements in the vanadate-induced inhibition of the human P-glycoprotein ATPase.
Rao US
Biochemistry; 1998 Oct; 37(42):14981-8. PubMed ID: 9778376
[TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein senses its substrates and the lateral membrane packing density: consequences for the catalytic cycle.
Aänismaa P; Gatlik-Landwojtowicz E; Seelig A
Biochemistry; 2008 Sep; 47(38):10197-207. PubMed ID: 18759452
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of the interaction of propranolol and timolol with model and biological membrane systems.
Herbette L; Katz AM; Sturtevant JM
Mol Pharmacol; 1983 Sep; 24(2):259-69. PubMed ID: 6888369
[TBL] [Abstract][Full Text] [Related]
17. Transition state P-glycoprotein binds drugs and modulators with unchanged affinity, suggesting a concerted transport mechanism.
Qu Q; Chu JW; Sharom FJ
Biochemistry; 2003 Feb; 42(5):1345-53. PubMed ID: 12564938
[TBL] [Abstract][Full Text] [Related]
18. Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket.
Loo TW; Bartlett MC; Clarke DM
Biochem J; 2006 Oct; 399(2):351-9. PubMed ID: 16813563
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein.
Bosch I; Dunussi-Joannopoulos K; Wu RL; Furlong ST; Croop J
Biochemistry; 1997 May; 36(19):5685-94. PubMed ID: 9153408
[TBL] [Abstract][Full Text] [Related]
20. Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol.
Kimura Y; Kioka N; Kato H; Matsuo M; Ueda K
Biochem J; 2007 Jan; 401(2):597-605. PubMed ID: 17029589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
